Published in J Pathol on June 28, 2012
Influence of tumour micro-environment heterogeneity on therapeutic response. Nature (2013) 4.78
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis (2014) 2.07
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest (2013) 2.03
The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov (2013) 1.93
Controlling escape from angiogenesis inhibitors. Nat Rev Cancer (2012) 1.81
Targeting prion-like protein doppel selectively suppresses tumor angiogenesis. J Clin Invest (2016) 1.39
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat Biotechnol (2012) 1.30
Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. J Exp Med (2013) 1.15
Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. CNS Oncol (2013) 1.05
Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov (2016) 1.03
Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. Front Pharmacol (2013) 1.02
Contrasting effects of sunitinib within in vivo models of metastasis. Angiogenesis (2012) 1.00
Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proc Natl Acad Sci U S A (2015) 0.96
Genetic targeting of sprouting angiogenesis using Apln-CreER. Nat Commun (2015) 0.92
Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Res (2013) 0.92
The VEGF signaling pathway in cancer: the road ahead. Chin J Cancer (2013) 0.91
Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. Clin Cancer Res (2013) 0.91
Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects. Nat Rev Clin Oncol (2016) 0.91
Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis. Clin Exp Metastasis (2013) 0.87
Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma. BMC Vet Res (2015) 0.85
Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy. J Clin Invest (2013) 0.84
Molecular Targeted Intervention for Pancreatic Cancer. Cancers (Basel) (2015) 0.80
AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer. Gynecol Oncol (2014) 0.79
Endothelial Rac1 is essential for hematogenous metastasis to the lung. Oncotarget (2015) 0.78
Quantification of Tumor Burden in a Genetically Engineered Mouse Model of Lung Cancer by Micro-CT and Automated Analysis. Transl Oncol (2015) 0.78
Establishment of an orthotopic pancreatic cancer mouse model: cells suspended and injected in Matrigel. World J Gastroenterol (2014) 0.75
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66
Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature (2006) 13.75
VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med (2008) 9.87
HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell (2003) 9.12
Autocrine VEGF signaling is required for vascular homeostasis. Cell (2007) 7.37
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature (2006) 6.56
Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest (2003) 6.44
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
Bayesian compressive sensing using laplace priors. IEEE Trans Image Process (2010) 4.93
Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell (2011) 4.78
Corneal avascularity is due to soluble VEGF receptor-1. Nature (2006) 4.77
Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science (2003) 4.56
Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A (2002) 4.46
Distinct thresholds govern Myc's biological output in vivo. Cancer Cell (2008) 4.16
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature (2009) 4.12
VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature (2002) 4.10
The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell (2003) 3.89
PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell (2009) 3.71
Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature (2007) 3.70
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest (2004) 3.47
Generation of a prostate from a single adult stem cell. Nature (2008) 3.46
A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell (2010) 3.34
Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem (2005) 3.30
Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell (2004) 3.28
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell (2002) 3.27
Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc Natl Acad Sci U S A (2002) 3.26
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol (2011) 3.23
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol (2010) 3.15
The vascular basement membrane: a niche for insulin gene expression and Beta cell proliferation. Dev Cell (2006) 3.10
The molecular basis of vascular lumen formation in the developing mouse aorta. Dev Cell (2009) 3.08
The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol (2007) 3.06
Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res (2005) 3.00
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med (2013) 3.00
Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer (2010) 2.93
Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol (2011) 2.83
Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A (2010) 2.77
Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res (2006) 2.75
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst (2005) 2.74
Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res (2011) 2.71
CXCR4 and CXCR7 have distinct functions in regulating interneuron migration. Neuron (2011) 2.69
G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A (2009) 2.68
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell (2013) 2.64
Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell (2010) 2.64
Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. J Clin Invest (2012) 2.58
Distinguishing cancer-associated missense mutations from common polymorphisms. Cancer Res (2007) 2.57
Role of VEGF-A in vascularization of pancreatic islets. Curr Biol (2003) 2.56
VEGFA is necessary for chondrocyte survival during bone development. Development (2004) 2.54
USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma. Cell (2011) 2.51
Short- and long-range attraction of cortical GABAergic interneurons by neuregulin-1. Neuron (2004) 2.51
A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci U S A (2009) 2.46
EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution. Development (2007) 2.45
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
CCR2 recruits an inflammatory macrophage subpopulation critical for angiogenesis in tissue repair. Blood (2012) 2.43
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 2.43
Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med (2009) 2.42
Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol (2005) 2.38
Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell (2008) 2.35
MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res (2008) 2.33
Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci U S A (2008) 2.30
Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling. Dev Biol (2003) 2.24
Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol (2007) 2.23
The Academy of Medical Royal Colleges' statement on clinical research in the UK. Lancet (2009) 2.23
VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J (2004) 2.22
Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J (2012) 2.21
Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation. Clin Immunol (2010) 2.19
B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol (2010) 2.17
Prognostic value of serum neutrophil gelatinase-associated lipocalin in metastatic and nonmetastatic colorectal cancer. World J Surg (2013) 2.12
Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol (2006) 2.10
Cellular patterns of transcription factor expression in developing cortical interneurons. Cereb Cortex (2006) 2.09
Distinct molecular pathways for development of telencephalic interneuron subtypes revealed through analysis of Lhx6 mutants. J Comp Neurol (2008) 2.09
Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res (2008) 2.08
Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS One (2009) 2.07
Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell (2004) 2.05
ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo. J Biol Chem (2002) 2.02
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A (2011) 2.01
A direct and melanopsin-dependent fetal light response regulates mouse eye development. Nature (2013) 1.98
A subpopulation of olfactory bulb GABAergic interneurons is derived from Emx1- and Dlx5/6-expressing progenitors. J Neurosci (2007) 1.94
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol (2010) 1.94
Peripheral nerve-derived VEGF promotes arterial differentiation via neuropilin 1-mediated positive feedback. Development (2005) 1.93